Examiner: HECK, BRYAN WILLIAM

Tech Center 1600 • Art Units: 1643 1645

This examiner grants 47% of resolved cases

Performance Statistics

46.9%

Allow Rate

-13.1% vs TC avg

Total Applications

+70.3%

Interview Lift

1318

Avg Prosecution Days

Based on 49 resolved cases, 2023–2026

4.5%

§101 Eligibility

7.5%

§102 Novelty

37.3%

§103 Obviousness

17.9%

§112 Clarity

App #	Title	Status	Assignee
18260377	ANTI-CD72 NANOBODIES FOR IMMUNOTHERAPY	Non-Final OA	The Regents of the University of California
18349012	METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R ANTAGONIST	Non-Final OA	REGENERON PHARMACEUTICALS, INC.
18476345	PHARMACEUTICAL COMPOSITION COMPRISING TOLL-LIKE RECEPTOR AGONIST AND STIMULATOR OF INTERFERON GENES AGONIST AND USE THEREOF	Non-Final OA	National Health Research Institutes

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.